Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)

NCT07744698 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

107

Enrollment

OTHER

Sponsor class

Conditions

Squamous Non-Small Cell Lung Cancer sqNSCLC
Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Interventions

DRUG: Paclitaxel Oral Solution
DRUG: PD-1/PD-L1 inhibitor (eg. Tislelizumab)

Sponsor

Anhui Provincial Cancer Hospital